Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-25

Clinical Trial Update: Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of AG-013736 in patients with iodine-131-refractory thyroid cancer has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AG-013736

Snippet

Sponsor: Pfizer | Conditions: Thyroid Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-11-25